Jacques PFISTER
MBA
-
Previously President of "CCI Marseille Provence"
CCI Marseille Provence
Unique cluster in the world exclusively dedicated to basic and applied immunology, MI results from an efficient territorial game between research, industry, and the institutional stakeholders in economy and innovation.
Marseille Immunopole is one spearheads of the Aix-Marseille-Provence Metropolis excellence, in research as in the economy field.
Unique cluster in the world exclusively dedicated to basic and applied immunology, MI results from an efficient territorial game between research, industry, and the institutional stakeholders in economy and innovation.
CCI Marseille Provence, already at the initiative of the Eurobiomed cluster, accompanies this ambitious metropolitan project in its entrepreneurial and international dimensions. Alongside with its institutional partners, it facilitates the development of companies and contributes to the development of this project.
Health is a major economical sector of Aix-Marseille-Provence Metropolis. Combining a high-level public and private healthcare offer with high research potential, it constitutes an expanding strategic sector for CCI Marseille Provence, which gave rise to numerous ambitious and innovative entrepreneurial initiatives.
Combined successes of Éric Vivier, a world-renowned researcher, Hervé Brailly and Vincent Fert, entrepreneurs who have both developed their companies in a remarkable way, illustrate perfectly the dynamism and the innovative capacity of our territory in this essential area.
Have a look on our testimonies
Thanks to this unprecedented alliance of researchers, clinicians, technological platforms and industrials we should be able to quickly do much better
Vincent BARLOGIS
AP-HM
The laboratory's mission therefore reflects that of the Marseille Immunopôle: to lead the development of these innovations, from the initial discovery to the proof of concept in clinical setting.
Florence SABATIER
AMU, AP-HM
MI should enable us to accelerate discovery, enhance our treatment options and offer more innovative options to our patients through current clinical trials and those of the future.
Fabrice BARLESI
AP-HM, AMU
We have developed a library of human tumors xenografted on immunodepressed mice
Michel IOVANNA JUAN
AMU, IPC, CRCM
your commitment to MI